Ultragenyx Pharmaceutical Inc.·4

Apr 20, 5:13 PM ET

Harris Erik 4

Research Summary

AI-generated summary

Updated

Ultragenyx (RARE) EVP Erik Harris Receives RSU Award

What Happened

  • Erik Harris, EVP & Chief Commercial Officer of Ultragenyx (RARE), was granted equity awards on 2026-04-16: 28,895 shares reported as acquired and 49,960 shares reported as a derivative acquisition, for a total of 78,855 restricted stock units (RSUs). The reported acquisition price for both entries is $0.00 (awards, not purchases). No cash was paid; these are compensation awards rather than open-market buys or sales.

Key Details

  • Transaction date: 2026-04-16; Form 4 filed: 2026-04-20 (period of report 4/16/2026).
  • Reported price: $0.00 (awarded RSUs, not a cash transaction).
  • Shares owned after the transaction: not specified in the filing.
  • Footnotes from the filing:
    • F1: RSUs granted under the 2023 Incentive Plan; vest 1/4 on each anniversary of the grant date and fully vest after four years.
    • F2: Includes previously reported shares of common stock underlying RSUs granted to the reporting person, which remain subject to vesting conditions.
    • F3: Describes a separate option vesting schedule (1/4 on first anniversary, then 1/48 monthly thereafter).
  • Filing timeliness: Form filed 4 days after the transaction date; Form 4s are typically due within two business days, so this filing appears delayed.

Context

  • These awards are compensation RSUs that convert into actual shares only as they vest; they are not immediate purchases or sales and therefore do not directly signal an insider buying or selling stock. Such grants are common for executive pay and retention.